Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900937 | 0.85 | PIN1 (0.49) | PIN1POLBCASP6 | |
| SCHEMBL9900759 | 0.85 | PPARG (0.43) | LTA4HEPHX2PPARGFFAR1PLA2G2A | |
| SCHEMBL9901204 | 0.84 | POLB (0.45) | PIN1POLBCASP6 | |
| SCHEMBL15262296 | 0.83 | POLB (0.43) | PIN1POLBCASP6FFAR1 | |
| SCHEMBL9901818 | 0.82 | POLB (0.43) | PIN1POLBCASP6PPARG | |
| SCHEMBL9905581 | 0.82 | PLA2G7 (0.52) | PIN1POLBCASP6 | |
| SCHEMBL9900964 | 0.81 | ALDH1A1 (0.43) | PIN1LTA4HEPHX2PPARGFFAR1 | |
| SCHEMBL9900916 | 0.81 | POLB (0.41) | PIN1POLBCASP6 | |
| SCHEMBL9900949 | 0.79 | THRB (0.44) | POLBCASP6 | |
| SCHEMBL9901720 | 0.79 | PIN1 (0.44) | PIN1POLBCASP6PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| EP-2649050-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2012075917-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252986-A1 | COMPOUNDS | LIPG, ENPP2, PLA2G1B | PIN1 1366/4885POLB 2258/4885CASP6 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.